# Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine

> **NCT01845337** · PHASE2 · COMPLETED · sponsor: **University of Edinburgh** · enrollment: 59 (actual)

## Conditions studied

- Gastrointestinal Cancer
- Cancer of Unknown Primary Site
- Pancreatic Cancer
- Bile Duct Neoplasms

## Interventions

- **DRUG:** Teysuno
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT01845337
- **Lead sponsor:** University of Edinburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-05
- **Primary completion:** 2020-03-18
- **Final completion:** 2020-10-08
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2023-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01845337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01845337, "Study to Compare Cardiovascular Side Effects of Teysuno Versus Capecitabine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01845337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*